SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...

Credit: Dexcom. Stelo is an integrated CGM that continuously measures, records, analyzes, and displays glucose values in individuals 18 years of age and older who are not on insulin. Dexcom’s Stelo ...

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...

Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...

Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose ...